Showing 1911-1920 of 9327 results for "".
Take 5: Promising Developments in Vitiligo Research
https://practicaldermatology.com/columns/take-5/promising-developments-in-vitiligo-research/21924/New studies suggest therapeutic pearls for the management of vitiligo and highlight new approaches to understanding the disorder.Take 5: New Developments in the Realm of STIs and STDs
https://practicaldermatology.com/columns/take-5/take-5-new-developments-in-the-realm-of-stis-and-stds/21969/New data and recent advancements highlight the importance of education and prevention.Take 5: Summer Skin Care Pearls to Share with Patients
https://practicaldermatology.com/columns/take-5/take-5-summer-skin-care-pearls-to-share-with-patients/21984/As summer approaches, here are five points you could mention to your patients about UV protection.Medical Dermatology Myths
https://practicaldermatology.com/topics/general-topics/medical-dermatology-myths/22036/Here are the facts about seven common misconceptions that may hinder effective patient care.The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.A New Era in Hidradenitis Suppurativa Care
https://practicaldermatology.com/topics/rare-disease/a-new-era-in-hidradenitis-suppurativa-care/56428/Remarkable innovation is happening in HS. Ultimately, it comes down to this: we are now able to provide patients with a level of care that was not previously possible because so many new therapies are being unlocked.The Road to Denver – Targeting IL-31: A Case-Based Journey
https://practicaldermatology.com/series/nemluvio-peer-network/the-road-to-denver-targeting-il-31-a-case-based-journey/56419/Join Dr Raj Chovatiya, Dr Mona Shahriari, and Dr Jonathan Silverberg as they discuss Targeting the IL-31 Neuroimmune Pathway: A Case-Based Approach. This Product Theater will take place Sunday, March 29, 2026, from 10:30–11:15 AM MT at the Colorado Convention Center, Theater 1 in Denver, Colorado. PFirst Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.From Training to Transformation: How Leaders Get the Most Out of Educating Their Team
https://practicaldermatology.com/issues/september-2025/from-training-to-transformation-how-leaders-get-the-most-out-of-educating-their-team/37640/Imagine investing thousands of dollars in staff time and tuition for the latest aesthetic techniques or business courses—sending employees to conferences or bringing in an expert for in-office training—only to watch those skills fade, or be underused or forgotten.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.